Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03417882
Title GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors BrightPath Biotherapeutics
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.